Table I.
Differentially expressed pathways between metastatic and non-metastatic osteosarcoma.
| Pathway term | p-value | Adjusted p-value |
|---|---|---|
| Targets of AML1-MTG8 fusion | 1.18E-06 | 0.006 |
| Leishmania infection | 3.09E-06 | 0.015 |
| NRAS signaling | 3.46E-06 | 0.016 |
| T lymphocyte and NK progenitor | 3.85E-06 | 0.018 |
| Endogenous pathway | 4.63E-06 | 0.022 |
| Liver cancer metastasis | 4.69E-06 | 0.022 |
| Trafficking and processing of endosomal TLR | 5.94E-06 | 0.028 |
| Chronic lymphocytic leukemia | 6.18E-06 | 0.029 |
| TARF6-mediated IRF7 activation in TLR7/8 or 9 signaling | 7.23E-06 | 0.034 |
| Thyroid cancer cluster 4 | 7.31E-06 | 0.035 |
| Tretinoin response | 8.19E-06 | 0.039 |
| NRAS vs. stromal stimulation | 8.61E-06 | 0.041 |
| Aging cerebellum | 8.64E-06 | 0.041 |
| MMP regulation of cytokines | 1.01E-05 | 0.048 |
NK, natural killer; TLR, Toll-like receptor; IRF7, interferon regulatory factor 7; MMP, matrix metalloproteinase.